Association of Midlife Inflammatory Markers With Cognitive Performance at 10-Year Follow-up

• Published in: Neurology Vol. 99; no. 20; p. e2294
• Main Authors: Kipinoinen, Teemu, Toppala, Sini, Rinne, Juha O, Viitanen, Matti H, Jula, Antti M, Ekblad, Laura L
• Format: Journal Article
• Language: English
• Published: United States 15.11.2022
• Subjects: Biomarkers; C-Reactive Protein; Cognition; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Humans; Inflammation; Interleukin-6; Male; Middle Aged; Prospective Studies; Tumor Necrosis Factor-alpha
• ISSN: 1526-632X
• DOI: 10.1212/WNL.0000000000201116

Chronic low-grade inflammation, commonly associated with cardiovascular diseases and risk factors, has been associated inconclusively with cognitive decline and dementia. The aim of our study was to evaluate whether low-grade inflammation, measured in midlife, is associated with a decline in cognitive performance after a 10-year follow-up. We hypothesized that low-grade inflammation, estimated by interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-α), and high-sensitivity CRP (hs-CRP), is a predictor of cognitive decline in the general population. This prospective cohort study is based on a Finnish nationwide, population-based Health 2000 Examination Survey, its supplemental examinations in 2000-2001, and the follow-up Health 2011 Survey. Cognitive performance at baseline and at follow-up was assessed with categorical verbal fluency (VF), word-list learning (WLL), and word-list delayed recall (WLDR). Baseline low-grade inflammation was measured with IL-6, TNF-α, and hs-CRP in 2001. Associations between low-grade inflammation and cognitive performance were analyzed with multivariable linear models adjusted for age, sex, education, genotype, type 2 diabetes, hypertension, hypercholesterolemia, body mass index, depressive symptoms, smoking, and baseline cognition. Nine hundred fifteen participants aged 45-74 years (median age 54 years, 55% women) were included in the analysis. Both higher IL-6 and TNF-α at baseline predicted poorer performance in VF and WLL at 10-year follow-up (VF: IL-6 β: -1.14, = 0.003, TNF-α β: -1.78, = 0.008; WLL: IL-6 β: -0.61, = 0.007, TNF-α β: -0.86, = 0.03). Elevated IL-6 also predicted a greater decline in VF and WLL after a 10-year follow-up (VF: β: -0.81, = 0.01; WLL: β: -0.53, = 0.008). Baseline TNF-α did not predict cognitive decline, and hs-CRP did not predict cognitive performance or decline after 10-years. Our results suggest that low-grade inflammation in midlife is an independent risk factor for poorer cognitive performance later in life. Of the studied markers, IL-6 and TNF-α seem to be stronger predictors for cognitive performance and decline than hs-CRP.